Welcome to our dedicated page for Health Catalyst SEC filings (Ticker: HCAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.
The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.
Health Catalyst, Inc. (HCAT) Form 144 summary: This notice reports a proposed sale of 3,138 restricted common shares through Morgan Stanley Smith Barney on 09/02/2025, with an aggregate market value of $10,552.15. The filer acquired these shares as restricted stock on 09/02/2025 as compensation. The filing also discloses two restricted stock sales by the same person in the past three months: 3,255 shares sold on 06/02/2025 for $11,831.27 and 6,057 shares sold on 06/05/2025 for $23,890.63. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
Health Catalyst, Inc. (HCAT) filing of Form 144 notifies the market that 2,613 shares of common stock will be offered for sale through Morgan Stanley Smith Barney on 09/02/2025. The filing lists an aggregate market value of $8,786.74 for the shares based on the transaction and shows 70,373,625 shares outstanding for the issuer.
The shares were acquired the same day, 09/02/2025, as restricted stock from Health Catalyst and are identified as compensation. The filer discloses a prior restricted-stock sale of 2,712 shares on 06/02/2025 yielding gross proceeds of $9,857.58. By signing, the person attests they are unaware of undisclosed material adverse information about the issuer.
Health Catalyst, Inc. (HCAT) Form 144 shows a proposed sale of 8,335 shares of common stock through Morgan Stanley Smith Barney on 09/02/2025 on the NASDAQ, with an aggregate market value of $28,028.10. The filing reports the shares were acquired the same day (09/02/2025) as restricted stock from Health Catalyst as compensation. The filer previously sold 8,658 restricted shares on 06/02/2025 for gross proceeds of $31,470.10. The total number of outstanding shares is listed as 70,373,625. By signing, the seller represents no undisclosed material adverse information about the issuer.
Health Catalyst, Inc. (HCAT) reported a Form 144 notice showing a proposed sale of 3,360 common shares through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $11,298.67. The shares were acquired the same day as restricted stock issued by Health Catalyst as compensation. The filing lists 70,373,625 shares outstanding and indicates no securities sold by the reporting person in the past three months. The filer certifies no undisclosed material adverse information and provides standard Form 144 representations.
Health Catalyst, Inc. (HCAT) filed a Form 144 notifying the proposed sale of 3,663 common shares through Morgan Stanley Smith Barney on 09/02/2025 with an aggregate market value of $12,317.57. The shares were acquired the same day as restricted stock from the issuer as compensation. The filing also discloses a prior sale by the same person on 06/02/2025 of 3,802 restricted shares for $13,819.51. The filing includes the required representation that the seller is not aware of undisclosed material adverse information.
Health Catalyst, Inc. reported revenue of $160.1 million for the six months ended June 30, 2025, up from $150.6 million a year earlier, driven by higher recurring technology revenue of $104.4 million (vs. $94.6 million). Despite revenue growth, operating costs and a $28.8 million goodwill impairment contributed to a wider six-month net loss of $64.7 million, or $0.94 per share, compared with a $34.1 million loss a year ago.
Cash and cash equivalents declined sharply to $50.7 million from $249.6 million at year-end, reflecting cash used to settle long-term obligations including the full cash settlement of convertible senior notes and acquisition activity (notably the Upfront acquisition with $80.0 million consideration). Total assets fell to $616.2 million and total liabilities to $268.6 million, leaving stockholders' equity of $347.5 million.